Xencor Analyst Price Targets - Benzinga

Xencor Inc

XNCRNASDAQ

Trade with Public

Trade with Public

$30.82

1.163.91%

마지막 업데이트: Nov 3, 1:14 PM

개요 뉴스 실적 전망 이벤트목표가재무 심리 지분 현황 비교 옵션 주식 보고서

Xencor Analyst Price Targets - Benzinga

Xencor Analyst Price Targets

Wall Street analyst price targets and consensus rating for Xencor (XNCR).

Price Target Range — 13 Quarters

Analyst Consensus — 15 Analysts

1S.Buy

12Buy

2Hold

Consensus RatingOverweight# Analysts15Avg. Consensus PT$35Upside to Avg. PT+13.6%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 27, 2026	Truist Securities	Gregory Renza	PT Raise	Buy	$29→$40
Oct 27, 2026	RBC Capital	Leonid Timashev	PT Raise	Outperform	$20→$43
Oct 27, 2026	Wells Fargo	Derek Archila	PT Raise	Overweight	$30→$44
Oct 27, 2026	Wedbush	David Nierengarten	PT Raise	Outperform	$30→$45
Oct 21, 2026	Wedbush	David Nierengarten	Maintained	Outperform	$30
Sep 28, 2026	Truist Securities	Gregory Renza	PT Raise	Buy	$27→$29
Sep 21, 2026	B of A Securities	Alec Stranahan	PT Raise	Neutral	$20→$26
Sep 11, 2026	Barclays	Etzer Darout	PT Raise	Overweight	$27→$35
Sep 3, 2026	JP Morgan	Brian Cheng	PT Raise	Neutral	$14→$21
Sep 1, 2026	Raymond James	Sean McCutcheon	PT Raise	Strong Buy	$40→$46
Aug 6, 2026	RBC Capital	Leonid Timashev	PT Raise	Outperform	$19→$20
Aug 6, 2026	Wedbush	David Nierengarten	PT Raise	Outperform	$26→$30
Aug 6, 2026	Cantor Fitzgerald	Steve Seedhouse	PT Raise	Overweight	$43→$44
Jul 30, 2026	Wedbush	David Nierengarten	Maintained	Outperform	$26
Jul 7, 2026	Truist Securities	Gregory Renza	PT Cut	Buy	$29→$27
May 11, 2026	JP Morgan	Brian Cheng	PT Raise	Neutral	$13→$14
Mar 24, 2026	JP Morgan	Brian Cheng	Downgrade	Overweight→Neutral	$18→$13
Feb 26, 2026	Barclays	Etzer Darout	PT Raise	Overweight	$26→$27
Dec 17, 2025	Barclays	Etzer Darout	PT Raise	Overweight	$23→$26
Nov 24, 2025	Truist Securities	Gregory Renza	Initiate	Buy	$29

Analyst Ratings News

PRO
Truist Securities Maintains Buy on Xencor, Raises Price Target to $40

Truist Securities analyst Gregory Renza maintains Xencor (NASDAQ:XNCR) with a Buy and raises the price target from $29 to $40.

Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on Xencor, Raises Price Target to $43

RBC Capital analyst Leonid Timashev maintains Xencor (NASDAQ:XNCR) with a Outperform and raises the price target from $20 to $43.

Benzinga Newsdesk

PRO
Wells Fargo Maintains Overweight on Xencor, Raises Price Target to $44

Wells Fargo analyst Derek Archila maintains Xencor (NASDAQ:XNCR) with a Overweight and raises the price target from $30 to $44.

Benzinga Newsdesk

PRO
Wedbush Maintains Outperform on Xencor, Raises Price Target to $45

Wedbush analyst David Nierengarten maintains Xencor (NASDAQ:XNCR) with a Outperform and raises the price target from $30 to $45.

Benzinga Newsdesk

Xencor Drug Shows Unprecedented Profile in Colorectal Cancer: Analyst

Xencor reports upbeat Phase 1 kidney cancer data for XmAb819 at ESMO 2026 and selects 400 mcg/kg as the primary proposed Phase 3 study dose.

Vandana Singh

PRO
Wedbush Reiterates Outperform on Xencor, Maintains $30 Price Target

Wedbush analyst David Nierengarten reiterates Xencor (NASDAQ:XNCR) with a Outperform and maintains $30 price target.

Benzinga Newsdesk